Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 10:40AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.09 Insider Own8.12% Shs Outstand70.89M Perf Week1.85%
Market Cap97.98M Forward P/E- EPS next Y-0.62 Insider Trans236.46% Shs Float65.48M Perf Month21.68%
Income-77.26M PEG- EPS next Q-0.20 Inst Own76.66% Short Float6.02% Perf Quarter10.89%
Sales31.12M P/S3.15 EPS this Y37.33% Inst Trans0.40% Short Ratio4.22 Perf Half Y20.61%
Book/sh1.99 P/B0.69 EPS next Y21.79% ROA-38.27% Short Interest3.94M Perf Year-86.83%
Cash/sh1.80 P/C0.76 EPS next 5Y- ROE-48.47% 52W Range0.59 - 10.77 Perf YTD30.95%
Dividend Est.- P/FCF- EPS past 5Y20.67% ROI-53.29% 52W High-87.23% Beta0.28
Dividend TTM- Quick Ratio6.74 Sales past 5Y74.29% Gross Margin67.36% 52W Low132.97% ATR (14)0.08
Dividend Ex-Date- Current Ratio6.74 EPS Y/Y TTM24.52% Oper. Margin-287.76% RSI (14)66.85 Volatility5.39% 6.86%
Employees91 Debt/Eq0.02 Sales Y/Y TTM0.95% Profit Margin-248.28% Recom2.78 Target Price1.84
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q43.39% Payout- Rel Volume1.31 Prev Close1.32
Sales Surprise24.33% EPS Surprise16.00% Sales Q/Q-5.14% EarningsMay 07 AMC Avg Volume933.18K Price1.38
SMA2011.27% SMA5017.68% SMA200-21.46% Trades Volume274,801 Change4.17%
Date Action Analyst Rating Change Price Target Change
Jan-22-24Downgrade H.C. Wainwright Buy → Neutral
Nov-13-23Downgrade William Blair Outperform → Mkt Perform
Oct-03-23Initiated Evercore ISI Outperform $22
Dec-14-22Initiated Stifel Buy $29
Dec-01-22Initiated Goldman Buy $25
Oct-06-22Initiated BTIG Research Buy $32
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Jul-16-24 04:01PM
Jul-02-24 01:27PM
Jun-06-24 07:00AM
May-08-24 12:06PM
04:06AM Loading…
May-07-24 10:56PM
Apr-30-24 07:00AM
Apr-23-24 08:00AM
Apr-05-24 09:40AM
Mar-20-24 09:40AM
Mar-14-24 08:45AM
12:00PM Loading…
Mar-04-24 12:00PM
Feb-27-24 09:35AM
Feb-15-24 10:00AM
Feb-13-24 09:40AM
Jan-17-24 11:14AM
Jan-16-24 07:00AM
Jan-10-24 07:00AM
Jan-04-24 09:40AM
Dec-19-23 04:01PM
Dec-05-23 04:01PM
Dec-04-23 09:35AM
Nov-16-23 09:35AM
10:57AM Loading…
Nov-14-23 10:57AM
Nov-13-23 07:17AM
Nov-06-23 08:03AM
Oct-03-23 07:00AM
Sep-20-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:03PM
Sep-08-23 05:06PM
Aug-10-23 06:07AM
Aug-08-23 08:40AM
Aug-07-23 08:15AM
Aug-01-23 07:53AM
Jul-06-23 08:19AM
Jun-26-23 10:15AM
Jun-13-23 06:30PM
Jun-02-23 07:00AM
May-18-23 01:50PM
May-10-23 06:04AM
May-08-23 11:55PM
May-05-23 06:49AM
May-02-23 07:01AM
Apr-27-23 04:35AM
Apr-24-23 02:37PM
Apr-04-23 07:40AM
Mar-27-23 07:00AM
Mar-10-23 11:34AM
Mar-06-23 03:59PM
Feb-23-23 08:35AM
Feb-22-23 06:01AM
Feb-09-23 04:01PM
Jan-06-23 07:01AM
Nov-29-22 07:00AM
Nov-26-22 01:39PM
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
Nov-08-22 08:25AM
Oct-26-22 06:44AM
Sep-27-22 07:00AM
Sep-15-22 06:46AM
Aug-30-22 07:00AM
Aug-25-22 07:00AM
Aug-05-22 07:59AM
Aug-03-22 08:25AM
Aug-01-22 07:00AM
Jul-15-22 12:00PM
Jul-08-22 09:40AM
Jul-01-22 09:36AM
Jun-27-22 07:00AM
Jun-22-22 09:40AM
Jun-20-22 08:20AM
Jun-13-22 09:55AM
Jun-06-22 09:40AM
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leonard Braden Michael10% OwnerJul 05 '24Buy1.15123,017141,33413,447,969Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJul 03 '24Buy1.16143,288166,07113,324,952Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJul 02 '24Buy1.1486,09298,48913,181,664Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJul 01 '24Buy1.14107,434122,18513,095,572Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJun 28 '24Buy1.121,201,0001,348,55912,988,134Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJun 27 '24Buy1.15235,000271,33111,787,134Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJun 18 '24Buy1.1350,00056,50511,552,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 17 '24Buy1.13150,000169,50011,502,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 14 '24Buy1.17345,000402,20111,352,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 13 '24Buy1.15528,621607,75711,007,134Jun 13 06:04 PM
Leonard Braden Michael10% OwnerJun 12 '24Buy1.1482,57994,14010,478,513Jun 13 06:04 PM
Leonard Braden Michael10% OwnerJun 11 '24Buy1.081,000,0001,080,00010,395,934Jun 13 06:04 PM
Powell Andrew Kenneth WilliamDirectorMar 04 '24Buy1.256,0007,50028,863Mar 05 04:58 PM
Powell Andrew Kenneth WilliamDirectorMar 01 '24Buy1.238,50010,45522,863Mar 05 04:58 PM
Monahan JosephChief Scientific OfficerOct 23 '23Sale5.086,00030,460129,724Oct 25 04:28 PM
Balthaser KevinChief Financial OfficerSep 06 '23Buy7.909,49074,97115,461Sep 07 04:16 PM
Loerop JamesChief Business OfficerAug 28 '23Buy6.8014,70599,95921,688Aug 28 04:39 PM
Monahan JosephChief Scientific OfficerAug 21 '23Sale7.326,00043,895135,724Aug 22 04:31 PM